Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.2600 (-1.88%) ($6.2600 - $6.2600) on Mon. Aug. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.37% (three month average) | RSI | 51 | Latest Price | $6.2600(-1.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.4% a day on average for past five trading days. | Weekly Trend | HTBX advances 0.9% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(53%) ARKG(52%) ARKK(51%) IBUY(49%) ONLN(49%) | Factors Impacting HTBX price | HTBX will decline at least -4.185% in a week (0% probabilities). VIXM(-32%) VXX(-29%) UUP(-14%) TLT(-11%) XLU(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.185% (StdDev 8.37%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.44 | 5 Day Moving Average | $6.48(-3.4%) | 10 Day Moving Average | $6.49(-3.54%) | 20 Day Moving Average | $6.44(-2.8%) | To recent high | -41.7% | To recent low | 2.3% | Market Cap | $689m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |